Market Cap 4.91B
Revenue (ttm) 1.56B
Net Income (ttm) 367.07M
EPS (ttm) N/A
PE Ratio 13.33
Forward PE 20.54
Profit Margin 23.57%
Debt to Equity Ratio 0.00
Volume 1,386,800
Avg Vol 1,881,280
Day's Range N/A - N/A
Shares Out 165.08M
Stochastic %K 94%
Beta 0.47
Analysts Strong Sell
Price Target $40.81

Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed product...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 353 1 772 8000
Address:
Connaught House, 1 Burlington Road Dublin 4, Dublin, Ireland
Quantumup
Quantumup Aug. 21 at 11:56 AM
UBS⬆️ $AVDL's PT to $20 from $13, reiterated at a Buy and said, we are raising our PT to $20 (from $13) as we layer in risk-adj peak sales of $340M for the IH indication, which has a Ph3 read-out in 1Q26. $CNTA $ALKS $AXSM $JAZZ UBS added:
1 · Reply
inelegantinvest
inelegantinvest Aug. 20 at 7:28 PM
Mural Oncology’s short run comes to an end. Alkermes’ 2023 biotech spin-off is being acquired by $XOMA after failed trials and heavy cash burn. What went wrong—and what does it mean for shareholders? Full story: https://www.stockspinoffs.com/2025/08/20/xoma-to-buy-failed-mural-ending-the-short-unsuccessful-run-of-the-alkermes-spinoff/ #Spinoffs #Biotech #XOMA $ALKS $XOMA
0 · Reply
inelegantinvest
inelegantinvest Aug. 20 at 7:23 PM
Mural Oncology’s short run comes to an end. Alkermes’ 2023 biotech spin-off is being acquired by $XOMA after failed trials and heavy cash burn. What went wrong—and what does it mean for shareholders? Full story: https://www.stockspinoffs.com/2025/08/20/xoma-to-buy-failed-mural-ending-the-short-unsuccessful-run-of-the-alkermes-spinoff/ #Spinoffs #Biotech #XOMA $ALKS $XOMA
0 · Reply
Quantumup
Quantumup Aug. 20 at 6:42 PM
RBC Capital reiterated $AXSM Outperform-$189 and said, FDA Flexibility On Mixed Data In Neuro-psych Gives Us Confidence AXS-05 Is Approvable In Alzheimer's Agitation. $OTSKY HLUBF HLBBF $ALKS $CNTA $BTAI ACAD With investors focused on the regulatory path for AXS-05 in Alzheimer' Agitation, we took the opportunity to review why we think the drug is approvable. We note the FDA demonstrates clear flexibility for missed endpoints in neuro-psychiatric drugs (with additional flexibility for drugs that have expedited designations), a clear acceptability for randomized withdrawal trials to support data packages, and ultimately, we believe that AXS-05's clears the bar for efficacy while demonstrating substantial safety improvements over standard of care that make an approval likely. Taken together, we would be buyers as we see substantial upside opportunity give a $1B+ U.S. opportunity, potential for an approval in 1H26, and believe shares can ultimately be up as much as 45% from current levels.
0 · Reply
Quantumup
Quantumup Aug. 20 at 4:35 PM
Truist reiterated $CNTA Buy-$30 and said, Don't Sleep On It: Previewing ORX750 Ph 2 Narcolepsy Data. $ALKS $JAZZ $AXSM $TAK HRMY #SLEEP2025 Truist additionally said in its note: ORX750 Ph 2a data are due sometime before YE. We believe investors are looking for a best-in-class profile from ORX750, and competitors' OX2R agonist data which will be presented at World Sleep [#SLEEP2025] (Sept 5-10) will set the bar for $CNTA. We think ORX750 is likely to demonstrate best-in-class properties in the approaching Ph 2a data, and see potential upside of~30% to >100% from current levels depending on the level of differentiation it shows.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Aug. 17 at 5:53 PM
Commercial-stage bio (oncology & non-oncology) actual Q2 2025 revenues versus consensus. We track 29 of the 35 oncology focused bios in this peer group & exclude those like $MRUS where we believe pipelines are the primary drivers of value potential (of course some may disagree) & all non-oncology with 1st approvals since 1/1/2017. In non-oncology, it is interesting to note the more mature bios like $ALKS & $SUPN and/or those with nearing patent expirations like $HRMY trade at lower multiples of actual Q2 25 revenues. Note Q2 2025 revenues may include non-recurring or one-time sales. Its our subjective opinion $IONS had the most impressive beat & raise (at least v. expectations 3 months ago). This is not investment advice. We're merely sharing our data tracker.
2 · Reply
Quantumup
Quantumup Aug. 14 at 12:18 PM
Stifel reitd $ALKS Buy/$42: At our Biotech Summer Summit, we sat down with $ALKS CEO Richard Pops to discuss the prospects of the orexin program ahead of the full ph2 NT1 data at World SLEEP in September. While the stock has traded somewhat sideways following the high-level topline release, we continue to believe in prospects of ALKS2680/alixorexton in narcolepsy and beyond. Here, $ALKS remains confident and discussed (1) the consistency on efficacy across all measures, with best-in-class potential (2) how at WORLD SLEEP they expect to share a robust dataset -- they see efficacy on cognitive/fatigue/quality-of-life endpoints as highly validating and (3) how in non-NT1 patients, the dose-response curve may be shifted, so they don't expect to necessarily see safety/tolerability issues (i.e. meaningfully higher AEs) even with higher dosing. We also briefly touched on the potential to move beyond sleep disorders, along with management's views on MFN, and tariffs. $BIIB $AXSM $JAZZ $CNTA #SLEEP2025
0 · Reply
MadMusk
MadMusk Aug. 7 at 6:23 PM
$ACAD $ALKS $AXSM $MIRM $TVTX another lie Contrary to records suggesting protection through 2034, the actual data shows: • Patent expires March 2030, per US patent US9993461
1 · Reply
MadMusk
MadMusk Aug. 7 at 6:22 PM
$ACAD $ALKS $AXSM $MIRM $TVTX No — according to Simply Wall St, TVTX’s Price-to-Sales (P/S) ratio is approximately 6.5×, while its peer average is around 12.7×. That means TVTX trades at about half the peer valuation, not a fraction of one.
0 · Reply
MadMusk
MadMusk Aug. 7 at 6:20 PM
$ACAD $ALKS $AXSM $MIRM $TVTX Price to Book 46 🤡 low multiples
0 · Reply
Latest News on ALKS
Alkermes: A More Than Solid Quarter

Jul 30, 2025, 5:08 PM EDT - 25 days ago

Alkermes: A More Than Solid Quarter


Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 2:47 PM EDT - 26 days ago

Alkermes plc (ALKS) Q2 2025 Earnings Call Transcript


Alkermes plc Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 7:00 AM EDT - 27 days ago

Alkermes plc Reports Second Quarter 2025 Financial Results


Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript

May 1, 2025, 11:21 AM EDT - 4 months ago

Alkermes plc (ALKS) Q1 2025 Earnings Call Transcript


Alkermes plc Reports First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 4 months ago

Alkermes plc Reports First Quarter 2025 Financial Results


Alkermes to Participate in Upcoming Investor Conferences

Feb 26, 2025, 4:00 PM EST - 6 months ago

Alkermes to Participate in Upcoming Investor Conferences


Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 2:40 PM EST - 6 months ago

Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript


Alkermes to Participate in Two Upcoming Investor Conferences

Nov 11, 2024, 4:00 PM EST - 10 months ago

Alkermes to Participate in Two Upcoming Investor Conferences


Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 1:04 PM EDT - 10 months ago

Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript


Alkermes plc Reports Third Quarter 2024 Financial Results

Oct 24, 2024, 7:00 AM EDT - 10 months ago

Alkermes plc Reports Third Quarter 2024 Financial Results


Alkermes plc (ALKS) Q2 2024 Earnings Call Transcript

Jul 24, 2024, 2:20 PM EDT - 1 year ago

Alkermes plc (ALKS) Q2 2024 Earnings Call Transcript


Alkermes plc Reports Second Quarter 2024 Financial Results

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Alkermes plc Reports Second Quarter 2024 Financial Results


The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 17, 2024, 8:27 AM EDT - 1 year ago

The Bottom Fishing Club: Alkermes Has Great Value And Safety


Alkermes plc Reports First Quarter 2024 Financial Results

May 1, 2024, 7:00 AM EDT - 1 year ago

Alkermes plc Reports First Quarter 2024 Financial Results


Alkermes plc: Collecting The Fruits Of The 2023 Spinoff

Apr 9, 2024, 9:49 AM EDT - 1 year ago

Alkermes plc: Collecting The Fruits Of The 2023 Spinoff


Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 3:08 PM EST - 1 year ago

Alkermes plc (ALKS) Q4 2023 Earnings Call Transcript


Quantumup
Quantumup Aug. 21 at 11:56 AM
UBS⬆️ $AVDL's PT to $20 from $13, reiterated at a Buy and said, we are raising our PT to $20 (from $13) as we layer in risk-adj peak sales of $340M for the IH indication, which has a Ph3 read-out in 1Q26. $CNTA $ALKS $AXSM $JAZZ UBS added:
1 · Reply
inelegantinvest
inelegantinvest Aug. 20 at 7:28 PM
Mural Oncology’s short run comes to an end. Alkermes’ 2023 biotech spin-off is being acquired by $XOMA after failed trials and heavy cash burn. What went wrong—and what does it mean for shareholders? Full story: https://www.stockspinoffs.com/2025/08/20/xoma-to-buy-failed-mural-ending-the-short-unsuccessful-run-of-the-alkermes-spinoff/ #Spinoffs #Biotech #XOMA $ALKS $XOMA
0 · Reply
inelegantinvest
inelegantinvest Aug. 20 at 7:23 PM
Mural Oncology’s short run comes to an end. Alkermes’ 2023 biotech spin-off is being acquired by $XOMA after failed trials and heavy cash burn. What went wrong—and what does it mean for shareholders? Full story: https://www.stockspinoffs.com/2025/08/20/xoma-to-buy-failed-mural-ending-the-short-unsuccessful-run-of-the-alkermes-spinoff/ #Spinoffs #Biotech #XOMA $ALKS $XOMA
0 · Reply
Quantumup
Quantumup Aug. 20 at 6:42 PM
RBC Capital reiterated $AXSM Outperform-$189 and said, FDA Flexibility On Mixed Data In Neuro-psych Gives Us Confidence AXS-05 Is Approvable In Alzheimer's Agitation. $OTSKY HLUBF HLBBF $ALKS $CNTA $BTAI ACAD With investors focused on the regulatory path for AXS-05 in Alzheimer' Agitation, we took the opportunity to review why we think the drug is approvable. We note the FDA demonstrates clear flexibility for missed endpoints in neuro-psychiatric drugs (with additional flexibility for drugs that have expedited designations), a clear acceptability for randomized withdrawal trials to support data packages, and ultimately, we believe that AXS-05's clears the bar for efficacy while demonstrating substantial safety improvements over standard of care that make an approval likely. Taken together, we would be buyers as we see substantial upside opportunity give a $1B+ U.S. opportunity, potential for an approval in 1H26, and believe shares can ultimately be up as much as 45% from current levels.
0 · Reply
Quantumup
Quantumup Aug. 20 at 4:35 PM
Truist reiterated $CNTA Buy-$30 and said, Don't Sleep On It: Previewing ORX750 Ph 2 Narcolepsy Data. $ALKS $JAZZ $AXSM $TAK HRMY #SLEEP2025 Truist additionally said in its note: ORX750 Ph 2a data are due sometime before YE. We believe investors are looking for a best-in-class profile from ORX750, and competitors' OX2R agonist data which will be presented at World Sleep [#SLEEP2025] (Sept 5-10) will set the bar for $CNTA. We think ORX750 is likely to demonstrate best-in-class properties in the approaching Ph 2a data, and see potential upside of~30% to >100% from current levels depending on the level of differentiation it shows.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Aug. 17 at 5:53 PM
Commercial-stage bio (oncology & non-oncology) actual Q2 2025 revenues versus consensus. We track 29 of the 35 oncology focused bios in this peer group & exclude those like $MRUS where we believe pipelines are the primary drivers of value potential (of course some may disagree) & all non-oncology with 1st approvals since 1/1/2017. In non-oncology, it is interesting to note the more mature bios like $ALKS & $SUPN and/or those with nearing patent expirations like $HRMY trade at lower multiples of actual Q2 25 revenues. Note Q2 2025 revenues may include non-recurring or one-time sales. Its our subjective opinion $IONS had the most impressive beat & raise (at least v. expectations 3 months ago). This is not investment advice. We're merely sharing our data tracker.
2 · Reply
Quantumup
Quantumup Aug. 14 at 12:18 PM
Stifel reitd $ALKS Buy/$42: At our Biotech Summer Summit, we sat down with $ALKS CEO Richard Pops to discuss the prospects of the orexin program ahead of the full ph2 NT1 data at World SLEEP in September. While the stock has traded somewhat sideways following the high-level topline release, we continue to believe in prospects of ALKS2680/alixorexton in narcolepsy and beyond. Here, $ALKS remains confident and discussed (1) the consistency on efficacy across all measures, with best-in-class potential (2) how at WORLD SLEEP they expect to share a robust dataset -- they see efficacy on cognitive/fatigue/quality-of-life endpoints as highly validating and (3) how in non-NT1 patients, the dose-response curve may be shifted, so they don't expect to necessarily see safety/tolerability issues (i.e. meaningfully higher AEs) even with higher dosing. We also briefly touched on the potential to move beyond sleep disorders, along with management's views on MFN, and tariffs. $BIIB $AXSM $JAZZ $CNTA #SLEEP2025
0 · Reply
MadMusk
MadMusk Aug. 7 at 6:23 PM
$ACAD $ALKS $AXSM $MIRM $TVTX another lie Contrary to records suggesting protection through 2034, the actual data shows: • Patent expires March 2030, per US patent US9993461
1 · Reply
MadMusk
MadMusk Aug. 7 at 6:22 PM
$ACAD $ALKS $AXSM $MIRM $TVTX No — according to Simply Wall St, TVTX’s Price-to-Sales (P/S) ratio is approximately 6.5×, while its peer average is around 12.7×. That means TVTX trades at about half the peer valuation, not a fraction of one.
0 · Reply
MadMusk
MadMusk Aug. 7 at 6:20 PM
$ACAD $ALKS $AXSM $MIRM $TVTX Price to Book 46 🤡 low multiples
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Aug. 7 at 4:32 PM
We struggle to understand why $TVTX trades at such a low multiple of projected revenues compared to peers. TVTX, like $MIRM, reported an impressive quarter. This is not to bash MIRM but rather highlight TVTX. We know Filspari has a 1/2026 PDUFA date in FSGS. Many TVTX peers have upside from pipelines. Cut TVTX projected sales by 40% & TVTX still trades below 0.20X 10-year sales TVTX makes medicines that target the kidney while MIRM the liver. TVTX's gross margins are higher yet TVTX trades at 1/3 MIRM's 10-year revenue multiple? As noted on the attachment, most M&A transactions are priced at 0.32 to 0.42X 10-year revenues. Other TVTX peer independent comm'l-stage bios (not perfect comps but...) trade at 0.21 to 0.30X. 5 are provided at the bottom including $AXSM $ALKS & $ACAD Our records indicate TVTX's Filspari is patented through 7/14/2034. Are we missing anything else?
2 · Reply
inelegantinvest
inelegantinvest Aug. 5 at 11:28 AM
🎨 Another one bites the dust: Mural Oncology $MURA will wind down after nemvaleukin alfa fails in the clinic. 💸 From $275M to <$50M in under 2 years. 🧾 Shareholders may get < $2/share. Full story → https://stockspinoffs.com/2025/08/05/mural-oncology-paints-itself-into-a-corner-after-nemvaleukin-alfa-fails/ $ALKS
0 · Reply
ZacksResearch
ZacksResearch Jul. 30 at 3:48 PM
$ALKS just beat Q2 earnings — but here's the real driver 📈 Proprietary product sales jumped 14% year over year, helping offset declines in manufacturing and royalty revenue. See what this means for the next leg in ALKS 👉 https://www.zacks.com/stock/news/2639254/alkermes-q2-earnings-beat-estimates-proprietary-drugs-aid-sales?cid=sm-stocktwits-2-2639254-teaser-4814&ADID=SYND_STOCKTWITS_TWEET_2_2639254_TEASER_4814
0 · Reply
ZacksResearch
ZacksResearch Jul. 30 at 2:24 PM
$ALKS Q2 Earnings: Beating Estimates but Facing Challenges 📉 Alkermes reported EPS of 52 cents, topping the Zacks Consensus Estimate of 41 cents. Yet, total revenues fell 2.1% from the year-ago quarter to $390.7M, despite a strong performance from proprietary products like Vivitrol, Aristada, and Lybalvi. Discover the full earnings breakdown 👉 https://www.zacks.com/stock/news/2639254/alkermes-q2-earnings-beat-estimates-proprietary-drugs-aid-sales?cid=sm-stocktwits-2-2639254-body-4757&ADID=SYND_STOCKTWITS_TWEET_2_2639254_BODY_4757
0 · Reply
Estimize
Estimize Jul. 29 at 10:18 PM
$ALKS reported 0.67 EPS and 390.66 revenue for Q2. http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_content=ALKS&utm
0 · Reply
JarvisFlow
JarvisFlow Jul. 29 at 12:30 PM
Needham updates rating for Alkermes ( $ALKS ) to Buy, target set at 45.
0 · Reply
LordHoven
LordHoven Jul. 29 at 11:08 AM
$ALKS https://www.prnewswire.co.uk/news-releases/alkermes-plc-reports-second-quarter-2025-financial-results-302515338.html
0 · Reply
StockHunter75
StockHunter75 Jul. 28 at 1:32 PM
$ALKS load up
0 · Reply
Estimize
Estimize Jul. 24 at 12:03 PM
Wall St is expecting 0.45 EPS for $ALKS Q3 [Reporting 10/22 BMO] http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_co
0 · Reply
ZacksResearch
ZacksResearch Jul. 22 at 6:04 PM
$ALKS down nearly 9% — even after positive trial results? 👀 Alixorexton met primary goals in narcolepsy type 1, but concerns around cataplexy data spooked investors. Full story behind the drop 👉 https://www.zacks.com/stock/news/2603277/alks-down-despite-positive-top-line-data-from-narcolepsy-study?cid=sm-stocktwits-2-2603277-teaser-3181&ADID=SYND_STOCKTWITS_TWEET_2_2603277_TEASER_3181
0 · Reply
ZacksResearch
ZacksResearch Jul. 22 at 1:30 PM
After a positive trial, why did $ALKS drop 8.8%? 🤔 Despite promising phase II results for alixorexton in narcolepsy treatment, only the 6 mg dose showed significant results in reducing cataplexy, possibly disappointing investors. Full analysis here 👉 https://www.zacks.com/stock/news/2603277/alks-down-despite-positive-top-line-data-from-narcolepsy-study?cid=sm-stocktwits-2-2603277-body-2998&ADID=SYND_STOCKTWITS_TWEET_2_2603277_BODY_2998
0 · Reply
Estimize
Estimize Jul. 22 at 12:15 PM
Wall St is expecting 0.34 EPS for $ALKS Q2 [Reporting 07/29 BMO] http://www.estimize.com/intro/alks?chart=historical&metric_name=eps&utm_co
0 · Reply